Microbix Biosystems Inc.
Microbix Biosystems is a life science company and leading manufacturer of viral and bacterial antigens and reagents for the global diagnostics industry.
Our expertise in cell biology has led to the development of new products: LumiSort, an animal reproductive product for use in livestock industries; Kinlytic, a biopharmaceutical used to treat blood clots; and VIRUSMAX, a technology used to increase influenza vaccine manufacturing yields. We are a public company listed on the Toronto Stock Exchange (TSX: “MBX”) focused on delivering value to our shareholders by growing our virology products business, as well as commercializing our new products including LumiSort and Kinlytic. In 2013 we reset the Company’s strategic priorities to focus on improving the productivity and growth potential of our diagnostics unit, while at the same time refocusing our new products to achieve near-term value driving milestones.
Microbix’ employees are talented and caring professionals who are responsible for developing sophisticated science and technology applications, operating highly technical manufacturing processes and managing complex global business relationships. In all of our activities we adhere to the following guiding principles:
Putting People First. whether business partners, patients or colleagues we are committed to effectively serving the needs of others in everything we do.
Commitment to Innovation. we must ‘think differently’ to ensure we remain strong and continue to grow and sustain our competitive edge.
Integrity and Ethics. we must ‘do the right thing’ and exercise care and good judgement in all of our activities.
Quality and Continuous Improvement. we must strive for a high standard of performance and be recognized for doing so by all of our stakeholders.